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Objectives: The extracellular signal-regulated kinase pathway of the mitogen-
activated protein kinase signal transduction cascade has been implicated in the
neuronal and endothelial dysfunction witnessed following cerebral ischemia-reper-
fusion injury. Extracellular signal-regulated kinase is activated by mitogen-activated
protein kinase/extracellular signal-regulated kinase 1/2. We evaluated the ability of
a mitogen-activated protein kinase/extracellular signal-regulated kinase 1/2–specific
inhibitor (U0126) to block extracellular signal-regulated kinase activation and
mitigate ischemic neuronal damage in a model of deep hypothermic circulatory
arrest.
Methods: Piglets underwent normal flow cardiopulmonary bypass (control, n  4),
deep hypothermic circulatory arrest (n 6), and deep hypothermic circulatory arrest
with U0126 (n 5) at 20°C for 60 minutes. The deep hypothermic circulatory arrest
with U0126 group was given 200 g/kg of U0126 45 minutes prior to initiation of
bypass followed by 100 g/kg at reperfusion. Following 24 hours of post–cardio-
pulmonary bypass recovery, brains were harvested. Eleven distinct cortical regions
were evaluated for neuronal damage using hematoxylin and eosin staining. A
section of ischemic cortex was further evaluated by immunohistochemistry with
rabbit polyclonal antibody against phosphorylated extracellular signal-regulated
kinase 1/2.
Results: The deep hypothermic circulatory arrest and deep hypothermic circu-
latory arrest with U0126 groups displayed diffuse ischemic changes. However,
the deep hypothermic circulatory arrest with U0126 group possessed signifi-
cantly lower neuronal damage scores in the right frontal watershed zone of
cerebral cortex, basal ganglia, and thalamus (P  .05) and an overall trend
toward neuroprotection versus the deep hypothermic circulatory arrest group.
This neuroprotection was accompanied by nearly complete blockade of phos-
phorylated extracellular signal-regulated kinase in the cerebral vascular endo-
thelium.
Conclusions: In this experimental model of deep hypothermic circulatory arrest,
U0126 blocked extracellular signal-regulated kinase activation and provided a
significant neuroprotective effect. These results support targeting of the extracellular
signal-regulated kinase pathway for inhibition as a novel therapeutic approach to
mitigate neuronal damage following deep hypothermic circulatory arrest.
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Despite the known risk of neurologic se-quelae, deep hypothermic circulatory ar-rest (DHCA) remains an important ele-ment in the repair of complex congenitalheart defects. Although DHCA has con-tributed to the improvement of surgical
results in neonates with congenital heart disease, little
progress has been made in our ability to ameliorate the
associated neurologic morbidity. Central nervous system
sequelae such as seizures, neurocognitive deficits, develop-
mental delay, and motor dysfunction occur in 5% to 45% of
survivors.1,2 This unacceptably high rate of neurologic com-
plications has stimulated the development of novel neuro-
protective strategies for the prevention of neuronal damage
in patients undergoing DHCA.3-7
Mitogen-activated protein kinases (MAPKs) represent a
family of highly conserved serine/threonine protein enzyme
complexes that are critical components of the enzyme cas-
cade systems that connect a wide variety of cell surface
receptors to critical cellular targets.8 MAPKs are activated
during ischemia and/or reperfusion and contribute to the
structural and functional changes associated with ischemia-
reperfusion (I/R) injury.9 Recent studies demonstrate that
members of the MAPK signal transduction cascade, most
notably extracellular signal-regulated kinase 1/2 (ERK1/2),
c-Jun amino-terminal kinase (JNK), and p38 protein (p38),
are activated following I/R in the brain,10,11 heart,12,13 kid-
ney,14,15 and liver.16 The ERK1/2 subfamily, which is ac-
tivated by MAPK/ERK kinase 1/2 (MEK1/2), has been
heavily implicated in the neuronal and endothelial dysfunc-
tion witnessed following cerebral I/R injury.10 Pharmaco-
logic studies with MEK1/2-specific inhibitors PD98059,17
1,4-diamino-2,3-dicyano-1,4-bis[2-aminophenylthio]buta-
diene (U0126),18 and SL32719 have shown that inhibition of
the ERK1/2 pathway significantly reduces neuronal damage
following cerebral ischemia and cerebral I/R injury.
The recognition that neuronal damage following cerebral
I/R injury may involve ERK1/2 activation has opened up a
new and exciting opportunity for the pharmacologic mod-
ulation of cerebral tolerance to DHCA. Previous work by
our group demonstrated that the ERK1/2 pathway is acti-
vated following DHCA and linked the expression of
p-ERK1/2 within cerebral vascular endothelium to the post-
ischemic neuronal damage seen following DHCA (unpub-
lished data). The present study evaluated the ability of the
MEK1/2-specific inhibitor (U0126) to block ERK1/2 acti-
vation and mitigate ischemic neuronal damage in a clini-
cally applicable model of DHCA (Figure 1). Additionally,
immunohistochemistry was performed to qualitatively cor-
relate the presence of phosphorylated ERK1/2 (p-ERK1/2)
expression in the cerebral vascular endothelium with the
degree of neuronal damage present 24 hours following
DHCA.
Materials and Methods
Animals and Surgical Preparation
Fifteen neonatal Duroc piglets with a mean body weight of 7.6 kg
(range 5.6-10.3 kg) were divided into 3 groups: normal flow,
normothermic cardiopulmonary bypass (CPB control, n  4),
DHCA (DHCA, n  6), or DHCA with U0126 (DHCA  U, n 
5). All animals received humane care in compliance with the
Principles of Laboratory Animal Care formulated by the National
Society for Medical Research and with the Guide for the Care and
Use of Laboratory Animals prepared by the Institute of Laboratory
Animal Resources and published by the National Institute of
Health (NIH publication no. 85-23, revised in 1985). Piglets were
sedated with intramuscular ketamine (20 mg/kg) and aceproma-
zine (0.03 mg/kg), transported to the laboratory, and attached to a
continuous pulse oximeter (Vet/Ox BP Plus 6500, Heska Co, Fort
Collins, Colo). Inhalational anesthesia with 1.5% to 2.5% isoflu-
orane was administered via a fitted, rubber-sealed mask. Once the
animal reached a plane of surgical anesthesia as determined by
toe-pinch response, jaw tone, heart rate, and response to stimula-
tion, a rapid tracheostomy was performed with a 3.5- to 4.5-mm
endotracheal tube. The piglets were ventilated with an FIO2 of 1.0,
tidal volumes of 10 to 15 cc/kg, and a rate of 18 to 24 respirations
per minute (Modified Servo Anesthesia-Ventilator 900C, Siemens
Pediatric, Sweden) to achieve arterial oxygen tensions greater than
200 mm Hg and carbon dioxide tensions of 35 to 45 mm Hg.
Anesthesia was maintained by a continuous inhalation of 1.5% to
2.5% isofluorane throughout the entire experiment, except during
the period of CPB when an isofluorane infusion was given through
the bypass circuit. The right femoral artery and vein were cannu-
lated for arterial pressure monitoring (Digital Display, Gould,
Valley View, Ohio), collection of blood samples for blood gas
analyses (Blood Gas Analyzer, Synthesis 25, Instrumentation Lab-
oratory, Lexington, Mass), and administration of intravenous flu-
ids. Prior to arterial cannulation, 300 IU/kg of heparin was admin-
istered via the femoral venous cannula. A rectal temperature probe
(Yellow Springs Instrument Inc, Yellow Springs, Ohio) and su-
prapubic-indwelling bladder catheter were inserted. Following ad-
ministration of cephazolin (50 mg/kg IV) and a median sternot-
omy, bypass cannulas were placed into the ascending aorta (10F-
12F DLP, Medtronic Inc, Minneapolis, Minn), right atrium (16F-
20F DLP, Medtronic), and left atrium (10F DLP Vent Catheter,
Medtronic). Rectal temperature was maintained at 37°C except for
the period of induced hypothermia.
Conduct of CPB
The CPB circuit consisted of a Cobe nonpulsatile roller pump
(Cobe Cardiovascular Inc, Arvada, Colo), cardiotomy reservoir,
and hollow fiber membrane oxygenator (Minimax plus,
Medtronic). The circuit was primed with fresh whole blood col-
lected from an adult donor pig 1 day preoperatively, 2000 IU of
heparin, 1 g of calcium chloride, and 25 mEq of sodium bicarbon-
ate. Hematocrit was maintained between 26% and 30%. The total
priming volume was 700 to 800 mL. CPB was initiated at a flow
rate of 100 to 150 mL/kg per minute and adjusted to maintain a
mean arterial pressure of 50 to 60 mm Hg.
Piglets were then subjected to 1 of the following conditions. In
the CPB control group, piglets underwent normal flow (100 to 150
mL/kg/min), normothermic (37°C) CPB for 60 minutes without
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aortic crossclamping. In the DHCA and DHCA  U groups,
piglets were cooled to a rectal temperature of 20°C using a heat
exchanger and cooling blanket. CPB was then discontinued and the
piglets were maintained at 20°C for 60 minutes of DHCA. Myo-
cardial protection was afforded by the infusion of high potassium
blood cardioplegic solution (15 mL/kg, potassium concentration
20 mEq) and application of iced saline slush during DHCA.
Arterial blood gases were controlled using pH stat strategy. After
60 minutes, CPB was reinitiated and the piglets were warmed to a
rectal temperature of 37°C. Care was taken to avoid a temperature
difference between the perfusate and core temperature of more
than 8°C. Once the piglets were normothermic they were weaned
from CPB and decannulated. Protamine (1 mg/1000 IU heparin)
was administered following separation from CPB.
Administration
U0126 (Calbiochem, La Jolla, Calif), a potent and specific inhib-
itor of MEK1/2, was administered via the femoral vein in the
DHCA  U group (Figure 1). The piglets were given 200 g/kg
of U0126 45 minutes prior to initiation of CPB and 100 g/kg at
the time of reperfusion. The U0126 was dissolved in 0.25 mL of
dimethylsulfoxide (Sigma Chemical Co, St Louis, Mo).
Postoperative Management
After weaning from CPB, the animals remained intubated and
sedated and were allowed to recover for 24 hours. Physiologic data
were recorded every hour. To avoid postoperative adverse effect
(bias), arterial blood gases, electrolytes, and hemodynamics were
maintained within normal limits throughout the recovery period.
Upon completion of the experiment, the cranial vault was opened
and the fresh whole brain was transected at the level of C1 during
deep anesthesia in a state of stable hemodynamics and continuous
antegrade cerebral perfusion.
Brain Histology and Neuronal Damage
The resected brains were fixed in 10% neutral buffered formalin
and stored at room temperature for 2 weeks. The brains were then
sectioned coronally and examined. Sections were taken from the
following sites: (1) right frontal watershed area, (2) left frontal
watershed area, (3) right parietal watershed area, (4) left parietal
watershed area, (5) right temporal lobe and hippocampus, (6) left
temporal lobe and hippocampus, (7) basal ganglia, (8) anterior
thalamus, (9) cerebellum, (10) mesencephalon, (11) pons, and (12)
medulla oblongata. The tissue was processed overnight and sub-
sequently embedded in paraffin. Five-micron sections were cut on
a microtome, deparaffinized, and then stained with hematoxylin
and eosin. A single neuropathologist (M.J.) blinded to the exper-
imental group examined all specimens and scored the extent of
neuronal damage in each slide. A modified grading system of
Pulsinelli and colleagues20 was used to quantify neuronal damage.
Scores were assigned based on the following scale: 0  no
neuronal damage; 1  mild neuronal damage (rare or scattered
ischemic neurons or a section with scattered neurons and 1 col-
lection less than one 100 magnification field); 2  moderate
neuronal damage (scattered collections of ischemic neurons that
collectively occupy one to three 100 magnification fields); 3 
Figure 1. Mechanism of ERK1/2 cascade with specific MEK1/2 inhibitor U0126. ERK1/2, extracellular signal-
regulated kinases 1 and 2; MEK1/2, mitogen-activated protein kinase/extracellular signal-regulated kinase 1/2.
Reprinted from Bioorganic & Medicinal Chemistry Letters, Vol 8, Duncia JV, Santella JB 3rd, Higley CA, Pitts WJ,
Wityak J, Frietze WE, et al. MEK inhibitors: the chemistry and biological activity of U0126, its analogs, and
cyclization products. p 2839-44, copyright 1998, with permission from Elsevier.
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severe neuronal damage (ischemic collections of neurons that
collectively occupy four or more 100 magnification fields). His-
topathologic scores for each group represented the average among
the slides taken from each region. Ischemia was defined as nuclear
pyknosis, eosinophilia, and contraction of cytoplasm seen in neu-
rons in a high-powered field (100).
Immunohistochemistry for Phosphorylated ERK1/2
After 2 weeks of fixation, a section of the right frontal watershed
zone (WSZ) was examined by immunohistochemistry using poly-
clonal rabbit antibodies to p-ERK1/2 and total ERK1/2 (Cell
Signaling, Beverly, Mass). Immunohistochemistry was performed
on a Ventana ES automated immunostainer (Ventana, Tucson,
Ariz). Optimal conditions were determined separately for each
antibody. To avoid background and artifactual unmasking of
epitopes, no pretreatment was used. The antigen–antibody com-
plexes were visualized using an avidin-biotin complex detection
system (Vector Laboratories, Inc, Burlingame, Calif) with 3,3'-
diaminobenzidine as the chromogen. Sections were counterstained
with hematoxylin. No significant immunoreactivity for each anti-
body was observed when substituting the primary antibodies with
nonimmune rabbit serum or by skipping the primary antibodies.
The activation of ERK1/2 was assessed by the same blinded
neuropathologist (M.J.) as either nonsignificant (no or rare expres-
sion of p-ERK1/2) or significant (considerable positive expression
of p-ERK1/2).
Statistical Analysis
Values are presented as the mean  standard error of the mean.
The continuous variables were compared using an analysis of
variance. A general linear model repeated measures analysis of
variance was also employed to assess changes among groups from
baseline to 6, 12, and 24 hours postoperatively. Differences in
neuronal damage among the experimental groups were evaluated
using Kruskal-Wallis test. A univariate general linear model was
used to assess neuronal damage among groups after adjusting for
covariates. Statistical analyses were conducted with the SPSS 11.5
software package (SPSS Inc, Chicago, Ill).
Results
Comparison of Experimental Groups
A comparison of physiologic variables at baseline and 6, 12,
and 24 hours postoperatively (body weight, pH, PaCO2,
PaO2, hematocrit, Na, K, Ca2, HCO3, mean arterial blood
pressure, and FIO2) revealed only the PaO2 at 12 hours
postoperatively in the DHCA group to be a statistically
important variable (P  .033). The median total CPB time
excluding DHCA was significantly longer in the DHCA
group (87 minutes) and DHCA  U group (77 minutes)
versus the CPB control group (63 minutes). However, there
were no significant differences in intraoperative variables
between the DHCA and DHCA  U groups (Table 1).
Histologic Evaluation of Neuronal Damage
Neuronal damage in circulatory arrest. The quantita-
tive scores of neuronal damage for each area are displayed
in Table 2. The CPB control group demonstrated nonsig-
nificant neuronal damage in all areas. In contrast, piglets in
the DHCA group demonstrated significant neuronal damage
in the right and left frontal WSZs, right parietal WSZ, basal
ganglia, thalamus, and cerebellum (Figure 2). The neuronal
damage scores from the DHCA group were moderate to
severe in the 4 WSZs and mild to moderate in the hip-
pocampus, basal ganglia, thalamus, cerebellum, mesenceph-
alon, and pons.
Neuronal damage in circulatory arrest with U0126. In
comparison with the CPB control group, the DHCA  U
group demonstrated a more diffuse pattern of postischemic
neuronal changes. However, there were no statistically sig-
nificant differences in neuronal damage scores between the
2 groups (Table 2). The DHCA  U group possessed
significantly lower neuronal damage scores in the right
frontal WSZ (P  .009), basal ganglia (P  .05), and
thalamus (P  .05) and an overall trend toward neuropro-
tection versus the DHCA group (Figure 2). The significant
differences in neuronal damage seen in the right frontal
WSZ, basal ganglia, and thalamus were unchanged even
when covariates, such as the value for PaO2 at 12 hours in
the DHCA group, were taken into account.
Activation of ERK1/2. Immunohistochemistry staining
revealed significant expression of p-ERK1/2 in the cerebral
vascular endothelium in 3 of the 6 DHCA piglets at 24
hours postoperatively. In contrast, nonsignificant expression
of p-ERK1/2 appeared in the cerebral vascular endothelium
of animals from the CPB control and DHCA  U groups.







TCPB (min) 63.3 1.9*† 87.0 9.9 77.0 10.2
ACC (min) — 69.7 3.8 71.8 3.3
CA (min) — 60 60
Hematocrit (%)* 29.7 0.6 27.6 1.3 26.6 1.5
pH* 7.45 0.05 7.41 0.02 7.39 0.04
PaO2 (mm Hg)* 307.3 14.7 328.3 21.1 269.0 30.9
PaCO2 (mm Hg)* 38.5 2.6 36.2 2.2 41.4 1.9
MAP (mm Hg)* 59.3 1.7 57.6 2.5 56.6 3.1
Cooling time (min) — 32.8 2.9 27.4 2.2
Rewarming (min) — 40.0 4.9 46.0 4.7
CPB, Cardiopulmonary bypass; DHCA, deep hypothermic circulatory arrest;
DHCA  U, deep hypothermic circulatory arrest with U0126; TCPB, total
CPB time (not including DHCA time); ACC, aortic crossclamping time; pH,
arterial pH; PaCO2, arterial partial pressure of carbon dioxide; PaO2, arterial
partial pressure of oxygen; MAP, mean systemic arterial pressure. Values
are shown as mean  SE.
*Variables were measured at the midpoint of total CPB time for the CPB
control group and approximately 10 minutes prior to DHCA for the other
groups.
†P  .05, significant difference from the DHCA and DHCA  U groups by
Kruskal-Wallis test.
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Discussion
The MAPK signal transduction cascade has been found to
play a key role in the process of I/R injury in a variety of
organ systems.10-16 The ERK1/2 pathway of the MAPK
cascade has emerged as a key mediator of cerebral I/R
injury.10 Inhibition of this pathway in models of cerebral
ischemia and cerebral I/R injury provided a significant
neuroprotective effect.10,17,18 Additionally, our group has
previously established that the ERK1/2 pathway is activated
following DHCA and that an association exists between the
expression of p-ERK1/2 in the cerebral vascular endothe-
lium and the degree of neuronal damage present 24 hours
following DHCA (unpublished data). Our findings impli-
cated ERK1/2 activation in the pathogenesis of the post-
ischemic neuronal damage seen following DHCA for the
first time and established the validity of our model for use in
the study of the cerebral I/R injury associated with DHCA.
In the present study we examined the ability of an MEK1/
2-specific inhibitor (U0126) to block the expression of
p-ERK1/2 in the cerebral vascular endothelium and de-
crease ischemic neuronal damage following DHCA.
U0126 is a potent and highly specific inhibitor of
MEK1/2, the upstream kinase of the ERK1/2 molecule,
which noncompetitively binds the MEK1/2 molecule and














Right frontal WSZ 0 2.5 0.22 0.8 0.37 .010 .009
Left frontal WSZ 0 2.5 0.22 1.6 0.68 .010 .329
Right parietal WSZ 0.25 0.25 2.0 0.37 1.6 0.68 .019 .537
Left parietal WSZ 0.5 0.5 2.17 0.48 1.0 0.45 .067 .126
Hippocampus 0.25 0.25 1.0 0.26 1.0 0.32 .114 .99
Basal ganglia 0 1.5 0.22 0.6 0.24 .010 .05
Thalamus 0.25 0.25 1.5 0.34 0.2 0.2 .067 .05
Cerebellum 0 1.0 0.26 0.6 0.4 .038 .429
Mescencephalon 0 0.83 0.31 0.4 0.24 .114 .429
Pons 0 0.17 0.17 0.6 0.24 .762 .247
Medulla oblongata 0 0 0.2 0.2 .99 .662
NCPB, Normothermic cardiopulmonary bypass control; DHCA, deep hypothermic circulatory arrest; DHCA  U, deep hypothermic circulatory arrest with
U0126; WSZ, watershed zone of cerebral cortex. Values are shown as mean  SE. Score range 0 –3, representing no neuronal damage (0) and severe
damage (3). P values are by Mann-Whitney U test.
Figure 2. The average ischemic neuronal damage score by experimental groups and by regions of the piglet brains.
Data are shown as mean  SE. *P < .05, **P < .01 versus NCPB; significantly greater neuronal damage in the CA
group. #P < .05 versus CA; significantly less neuronal damage in the CA U group. NCPB, cardiopulmonary bypass
control group; CA, deep hypothermic circulatory arrest group; CA  U, deep hypothermic circulatory arrest 
U0126; WSZ, watershed zone of cerebral cortex; RF, right frontal; LF, left frontal; RP, right parietal; LP, left parietal;
HC, hippocampus; BG, basal ganglia; TH, thalamus; CBLL, cerebellum; MESEN, mesencephalon; MO, medulla
oblongata.
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prevents its phosphorylation and activation.21,22 The use of
U0126 blocks the ability of MEK1/2 to phosphorylate and
activate the ERK1/2 molecule and the pathway is rendered
inactive at this point (Figure 1). U0126 inhibits ERK1/2
activation in a dose-dependent manner both in vitro21 and in
vivo in ischemic cortical neurons.18 In our study, the U0126
dosing regimen was based upon the findings of Namura and
colleagues,18 who demonstrated maximal cerebral protec-
tion with a 200-g/kg intravenous pretreatment dose of
U0126, which resulted in a 42% reduction in infarction
volume in a rat stroke model. Based on these findings we
administered a 200-g/kg dose of U0126 45 minutes prior
to CPB in an attempt to achieve maximal neuronal protec-
tion in our model. Additionally, a half dose of U0126 was
given at the time of reperfusion in an attempt to lessen the
acute effects of the cerebral reperfusion injury. Using this
regimen we obtained nearly complete blockade of ERK1/2
activation in the cerebral vascular endothelium. In prelimi-
nary studies by our group, U0126 pretreatment given 10
minutes before DHCA was unable to adequately block
ERK1/2 activation (data not shown). However, when
U0126 was administered at this time the piglet was on CPB.
As a result, the dose of U0126 was diluted by the volume of
the CPB prime (700 mL). We believe that not only did these
piglets not receive an adequate dose of U0126, but that 10
minutes was not an adequate amount of time for pretreat-
ment of the brain. In contrast, when given 45 minutes prior
to the initiation of CPB, the dose of U0126 was not affected
by the volume of the priming solution and there was ade-
quate time for pretreatment of the piglet brain. These results
suggest that both the timing of U0126 administration and
the concentration administered are essential factors in the
production of an adequate blockade of ERK1/2 activation.
In the current study, an extensive assessment of the
neuronal damage present 24 hours following normothermic
CPB, DHCA, and DHCA  U was performed by a single,
blinded neuropathologist. Although the DHCA  U group
displayed diffuse ischemic changes, the ischemic damage
was not significant when compared with the normothermic
CPB control group (Figure 2). The treatment of the DHCA
 U group with U0126 resulted in significantly lower
neuronal damage scores in the right frontal WSZ, basal
ganglia, and thalamus and an overall trend toward neuro-
protection versus the DHCA group (Figure 2). These results
represent the first report of the ability of an inhibitor of the
ERK1/2 pathway to attenuate neuronal damage following
DHCA. In addition to our neuropathological analysis, sec-
tions of the right frontal WSZ were analyzed with immu-
nohistochemistry. All specimens from the normothermic
CPB control and the DHCA U groups were found to have
nonsignificant expression of p-ERK1/2 within the cerebral
vascular endothelium. In contrast, 3 of the 6 specimens from
the DHCA group possessed significant p-ERK1/2 expres-
sion. These findings suggest that the ERK1/2 pathway
serves as a key mediator of the cerebral I/R injury associ-
ated with DHCA and further demonstrate the ability of
U0126 to effectively block the activation of the ERK1/2
pathway in our model of DHCA. Overall, the present study
supports the selective targeting of the ERK1/2 pathway for
inhibition as a means of increasing cerebral tolerance to
DHCA and opens up several novel areas for future research.
Limitations of the Study
Prior to discussing the implications of our results, it is
important to address 2 important methodological aspects of
our study. First, the timing of the removal of the piglet
brains following DHCA was a critical element within this
study. Previous work has shown that following cerebral I/R
injury a minimum of 24 hours is required before an accurate
neuropathological assessment of the extent of neuronal
damage can be made.20 However, the peak time for ERK1/2
activation following cerebral I/R injury has been shown to
occur approximately 2 hours following reperfusion.10 Thus,
while the optimal time for analysis of cerebral vascular
endothelial ERK1/2 activation would have been prior to 24
hours, we chose to perform our analysis at this time to
ensure an accurate neuropathologic assessment of the effec-
tiveness of the U0126 molecule as an MEK1/2 inhibitor
within our model of DHCA.
Second, we did not utilize the perfusion-fixation method
of cerebral extraction. However, our method of rapid ex-
traction (5 minutes) under a state of stable hemodynamics
with continuous antegrade cerebral perfusion was found to
be reliable and safe. Analysis of the brains from the CPB
control group revealed no significant neuronal injury or
expression of p-ERK1/2. These findings demonstrate that
our method of extraction has not introduced experimental
error or bias into our findings.
Interpretation of Results
Although our pathologic and immunohistochemistry data
clearly demonstrated a significant neuroprotective effect of
U0126 following DHCA, a considerable degree of neuronal
damage remained in the DHCA  U group despite its use.
This suggests that the neuroprotective effect of U0126 may
result from a partial inhibition of the ERK1/2 pathway or
the complete inhibition of the ERK1/2 pathway circum-
vented in some manner by an unknown mechanism of
“cross talk” involving the other MAPK pathways (p-38 and
JNK). Additionally, the effects of other inflammatory cas-
cades, such as the nuclear factor kappa beta cascade, were
not accounted for by this study and may be responsible for
the remaining neuronal damage seen in the DHCA  U
group. Therefore, future studies are required to elucidate the
exact mechanism of the neuroprotective effect of U0126
and to identify the cross talk that exists between the various
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pathways of the MAPK cascade and between the MAPK
cascade and other proinflammatory cascades.
Although the results of our immunohistochemical anal-
yses are encouraging, they must be cautiously interpreted.
These results represent the initial evidence of a link between
the presence of cerebral vascular endothelial expression of
p-ERK1/2 and a more extensive pattern of neuronal damage
24 hours following DHCA. However, we recognize that the
significance of such results must be weighed against 2
important factors. Initially, it must be understood that such
immunohistochemical analyses yield qualitative and not
quantitative results. Secondly, as previously stated, follow-
ing cerebral I/R injury the peak activation of ERK1/2 has
been shown to occur 2 hours following reperfusion. There-
fore, the fact that only 3 of the 6 piglets demonstrated
significant p-ERK1/2 expression in the cerebral vascular
endothelium 24 hours after DHCA was likely due to the
timing of cerebral extraction. To establish a more concrete
correlation between the cerebral vascular expression pattern
of p-ERK1/2 and the extent of neuronal damage seen fol-
lowing DHCA, further studies are required to examine the
early activation pattern of the ERK1/2 pathway following
DHCA. Ongoing studies in our laboratory are aimed at
qualitatively and quantitatively assessing the cerebral vas-
cular endothelial expression pattern of p-ERK1/2 2 hours
following DHCA and the effect of U0126 molecule at this
time point. We hope the evidence provided by these studies
will allow us to definitively correlate the neuronal protec-
tion achieved by the use of U0126 with the inhibition of
cerebral vascular endothelial p-ERK1/2 expression.
Finally, the promising results of our initial experience
with the inhibition of the ERK1/2 pathway of the MAPK
signal transduction cascade by U0126 must be viewed with
a global perspective of the role of the MAPK cascade in the
process of cerebral I/R injury. Cerebral I/R injury not only
activates the ERK1/2 subfamily of MAPK but also the p38
and JNK pathways, and the timing and magnitude of their
activation within the brain are distinct.10 These MAPK
cascades are not simple linear systems separately turned on
or off. A complex system of cross talk exists between all 3
of these important signal transduction pathways.23 In this
complex network the systematic inhibition of only 1 of
these pathways, as in our study, may have unpredictable
results. The problem becomes more complicated when the
whole body with its multiple different tissue types (organs)
is considered. Activation or inhibition of the same MAPK
pathway in 2 different tissues may lead to the expression of
different mediators with opposing roles.24 Thus, although
these MAPK pathways represent novel targets for the ther-
apeutic manipulation of inflammatory states and I/R injury,
caution is warranted because the systemic administration of
an inhibitor of a single MAPK subfamily targeting 1 organ
may achieve markedly different and unintended results in
other organs.23 Therefore, the overall benefit of studies such
as this depend upon continued research to outline the com-
plicated interaction between the pathways of the MAPK
cascade and their effects at a tissue-specific level.
Conclusion
In summary, our findings confirm the ability of our model of
DHCA to induce significant neuronal damage and activate
ERK1/2 24 hours postoperatively. Furthermore, we have
provided the first known report of the ability of the MEK1/
2-specific inhibitor, U0126, to attenuate the neuronal dam-
age associated with the use of DHCA. These results support
the targeting of the MAPK cascade and the ERK1/2 path-
way, in particular for inhibition as a novel therapeutic
approach to mitigate the cerebral injury and neurocognitive
dysfunction associated with DHCA. Future studies aimed at
further elucidating the role of the MAPK cascade and the
cross talk between its various pathways will help to clarify
the potential role of MAPK cascade inhibitors in the treat-
ment of cerebral I/R injury following DHCA. We hope that
such experiments will eventually result in the development
of a comprehensive pharmacologic neuroprotection strategy
for patients undergoing DHCA.
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Discussion
Dr Carmelo A. Milano (Durham, NC). There have been some
publications on the importance of administration of relatively high
doses of steroids in the neonatal pig model with cardiopulmonary
bypass. This has been shown to reduce fluid accumulation and also
preserve end-organ function. Were steroids a part of your proto-
col?
Dr Mulloy. No, sir, these animals did not receive any preop-
erative steroids.
Dr Milano. It would be interesting then to see what simple
administration of steroids would do in comparison to your inhib-
itor.
Dr Mulloy. Thank you for your suggestion. We will take that
into consideration when planning future experiments with this
model.
Dr Frank W. Sellke (Boston, Mass). MAPK is involved in a
lot of different mechanisms and pathways, including vasomotion.
Was there any hemodynamic effect of giving the MAPK inhibitor?
Dr Mulloy. No, sir, we did not see any significant hemody-
namic effects when we gave the inhibitor. The inhibitor was given
via a femoral venous line 45 minutes prior to initiation of cardio-
pulmonary bypass. At this time we had an arterial line in place and
the animals were attached to a pulse oximeter. Neither the blood
pressure or heart rate demonstrated any significant hemodynamic
change when the inhibitor was administered.
Dr Sellke. I have to commend you on your experimental
preparation. I put a lot of pigs on bypass and I find it is hard to keep
them alive for more than 3 hours after coming off bypass. What
was the perfusion pressure after the 24 hours of recovery?
Dr Mulloy. The protocol was to keep the perfusion pressure
around 40 to 50 mm Hg. At times we used small doses of
dopamine, approximately 3 to 7 mcg/kg/h, to maintain this pres-
sure. Overall, the average was in the 40 to 50 range.
Dr Sellke. MAPK is also involved with apoptosis. Do you
think this could have had some role in your beneficial effects that
you observed?
Dr Mulloy. Unfortunately we didn’t use terminal deoxynucleo-
tidyl transferase–mediated dUTP nick end labeling (TUNEL)
staining as a readout in this experiment; however, we are perform-
ing some additional experiments at the moment in which we are
going to include TUNEL staining as a readout. I think this will be
an interesting marker and hope that we will find some beneficial
effects of inhibitor administration in regard to apoptosis.
Dr Antonio F. Corno (Lausanne, Switzerland). You studied
very well the control of MAPK negative effects on piglets that I
presume were normoxic. We know that the vast majority of neo-
nates requiring deep hypothermia circulatory arrest are hypoxic or
cyanotic, and also we have seen MAPK implicated in the negative
effects not only in ischemia and reperfusion damage but also
hypoxia and reoxygenation damage, as we have demonstrated in
our research lab with hypoxic myocardium. Did you study any of
these protocols in hypoxic piglets, or are you planning to do it?
The second question is, what are the steps between this exper-
imental study and the potential clinical application?
Dr Mulloy. Thank you for your comments. Unfortunately, we
did not examine the role of hypoxia in this experiment. This was
our first attempt to develop an appropriate model in which we
could explore the effect of the MAPK cascade on cerebral isch-
emia/reperfusion injury, which I think is a very exciting area to
explore in cardiac surgery. So we tried to stick with something
fairly basic to begin; we are planning to expand from this point on.
In response to the first part of your question, no, we didn’t examine
hypoxic animals, but your suggestion would be a nice study to do
in the future.
As far as the potential steps from the bench to the bedside, I
think that this work is interesting, but I think it is only the tip of the
iceberg. We are looking at cerebral ischemia-reperfusion injury,
and, as we all know, there are not only multiple MAPK pathways
but there are multiple inflammatory cascades involved as well.
However, we were excited and are encouraged that the adminis-
tration of a single inhibitor was able to produce a significant
decrease in neuronal damage. Nevertheless, we realize that we
have a long road ahead of us and hope that future studies exam-
ining the effects of increasing the dose of the inhibitor and using
inhibitors of different pathways of MAPK cascade and, as well,
inhibitors of different inflammatory cascades may result in an
increased beneficial effect. I think that we are still quite a distance
from using this strategy at the bedside, but I think it is exciting
initial work and we are happy to proceed with it.
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